Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

ABSTRACT Aims In March 2024, the American Society of Clinical Oncology recommended the combination of tremelimumab plus durvalumab as a treatment for advanced hepatocellular carcinoma (HCC). Although safety data for first‐line treatments are available, information on adverse events related to late‐l...

Full description

Saved in:
Bibliographic Details
Main Authors: Naohiro Watanabe, Takashi Kobayashi, Michihiro Iwaki, Asako Nogami, Naohiro Wada, Ayako Shimizu, Tomoya Komori, Hirofumi Koike, Yukiko Sahashi, Atsushi Nakajima, Masato Yoneda
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:JGH Open
Subjects:
durvalumab
immune checkpoint inhibitors
treatment‐related adverse events
tremelimumab
unresectable hepatocellular carcinoma
Online Access:https://doi.org/10.1002/jgh3.70163
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jgh3.70163

Similar Items